She had a history of depression and anxiety, and had been receiving alprazolam 0.5mg thrice daily for 40years. Her sedatives, including benzodiazepines, were withheld. She initially improved; however, on ICU day4, her mental status acutely worsened with mutism and staring. On day5, there was...
[0024] Typically, the delivered aerosol has an inhalable aerosol drug mass density of between 0.02 mg/L and 10 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 0.05 mg/L and 5 mg/L. More preferably, the aerosol has an inhalable aerosol drug mass density...
Alprazolam was evaluated in chronic insomniacs in a 1-mg bedtime dose. The 16-night sleep laboratory protocol included four placebo-baseline nights followed by seven nights of drug administration and five placebo-withdrawal nights. On the first three drug nights (nights 5 to 7), the drug was ...
Each patient received alprazolam 2 mg on the first day (control) followed by two weeks of treatment with disulfiram 0.5 g/d, and then further oral dose of alprazolam 2 mg. No significant change was found in any of the kinetic parameters.Thus, a therapeutic dose of disulfiram did not ...
The subjects were randomized into one of three treatment groups: 0.25 mg q8h, 0.5 mg q8h, and 2 mg q12h. Subjects remained in the clinic for 8 days (day — 2-day 5). Day 0 was used as a drug free testing day to establish baseline scores for sedation, digit symbol substitution (DSS...
Clinical variables of anxiety, neuroticism, allostatic load, neurobiochemical studies, neurocognition and quality of life will be determined prior and periodically (1, 2, 4, 8, and 12weeks) after treatment (on demand of alprazolam from 0.75mg/day to 3.0mg/day). A sample of n=55/182 ...
Alprazolam 0,125 mg twice a day improves aspects of psychometric performance in healthy volunteers. J. Clin. Psychopharmacol., 18 : 364-372.Bourin M., Colombel M.C., Malinge M. Lorazepam 0.25 mg twice a day improves aspects of psychometric per- formance in healthy volunteers. ...
One Hundred chronic pain patients were begun on alprazolam, 1.5 mg/day. No other medication changes or therapeutic interventions were made. Sixteen patients were lost to follow-up and 1 oncology patient died. Of the 83 patients who were evaluated at 12 weeks, 61 (73.5%) showed improvement...
1 mg alprazolam was administered to 103 healthy Caucasian before, and after 5 days of treatment with 450 mg rifampicin. Alprazolam concentrations were measured at 0, 1h, 10h, 20h after each alprazolam intake by reverse phase HPLC. DNA sequence analysis was performed for coding and adjacent non-...
antagonist AM251 (0.3mg/kg). Likewise, intra-dlPAG injection of the 5-HT1A receptor agonist 8-OH-DPAT (3.2nmol/0.2uL) also reduced anxiety-like behavior, a response prevented by intra-dlPAG injection of AM251 (100pmol/0.2L). 8-OH-DPAT (8nmol/0.2L) also presented a panicolytic-like...